Cargando…

Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort

Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in adults with previously treated EGFR ex20ins+ metastatic non-small cell lung cancer (mNSCLC) in the EXCLAIM extension...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia Campelo, Maria Rosario, Zhou, Caicun, Ramalingam, Suresh S., Lin, Huamao M., Kim, Tae Min, Riely, Gregory J., Mekhail, Tarek, Nguyen, Danny, Goodman, Erin, Mehta, Minal, Popat, Sanjay, Jänne, Pasi A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821270/ https://www.ncbi.nlm.nih.gov/pubmed/36614913 http://dx.doi.org/10.3390/jcm12010112

Ejemplares similares

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial
por: Zhou, Caicun, et al.
Publicado: (2021)

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers
por: Zhang, Steven, et al.
Publicado: (2021)

Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products
por: Zhang, Steven, et al.
Publicado: (2021)

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study
por: Gupta, Neeraj, et al.
Publicado: (2022)

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
por: Imran, Mohd, et al.
Publicado: (2021)

Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes
por: Arnold, Abram, et al.
Publicado: (2023)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2023)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
por: Vasconcelos, Pedro E.N.S., et al.
Publicado: (2020)

Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
por: Kamel, Josette, et al.
Publicado: (2021)

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
por: Han, Han, et al.
Publicado: (2021)

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC
por: Strickland, Matthew R., et al.
Publicado: (2020)

Posters P788 - P999
Publicado: (2005)

Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations
por: Wang, Jun, et al.
Publicado: (2022)

The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non–small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations
por: Hernandez, Luis, et al.
Publicado: (2023)

Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
por: Gupta, Neeraj, et al.
Publicado: (2022)

Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report
por: Jia, Keyi, et al.
Publicado: (2022)

A report on the clinical-pathological correlations of 788 gingival lesion
por: Gambino, Alessio, et al.
Publicado: (2017)

Case–Control Genotyping of the c.788C>T Variant of Transforming Growth Factor-Beta 1 Gene in Otosclerosis in the South Indian Population
por: Kale, Deepa, et al.
Publicado: (2022)

Growth of Ceria Nano-Islands on a Stepped Au(788) Surface
por: Ma, Teng, et al.
Publicado: (2015)

788 INCREASE IN ALCOHOLIC HEPATITIS CASES DURING COVID PANDEMIC IN THE US
por: Nair, Geethu G., et al.
Publicado: (2021)

Correction to Lancet Child Adolesc Health 2022; 6: 788–98
Publicado: (2023)

Correction to Lancet Child Adolesc Health 2022; 6: 788–98
Publicado: (2022)

run 1193 - p = 11.788 GeV/c - 8.5.1981, Verification and adjustment of the compensation for EM608/1 at p = 11.788 GeV/c
por: Swoboda, Detlef
Publicado: (1981)

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
por: Kim, Dong-Wan, et al.
Publicado: (2022)

Human population and socioeconomic modulators of conservation performance in 788 Amazonian and Atlantic Forest reserves
por: de Marques, Ana Alice B., et al.
Publicado: (2016)

Butorphanol effectively prevents etomidate-induced myoclonus: a pooled analysis of 788 patients
por: Zhu, Yu, et al.
Publicado: (2018)

788. Therapeutic Drug Monitoring for Pyrazinamide During Tuberculosis Treatment: What Is the Diagnostic Accuracy?
por: Anderson, Ginger, et al.
Publicado: (2018)

Breast cancer morbidity and mortality in rural Ethiopia: data from 788 verbal autopsies
por: Ayele, Wondimu, et al.
Publicado: (2022)

Multiple primary malignancies in 788 Chinese patients with diffuse large B‐cell lymphoma
por: Zhang, Xuchang, et al.
Publicado: (2023)

Suicide in obsessive–compulsive disorder: a population-based study of 36 788 Swedish patients
por: Fernández de la Cruz, L, et al.
Publicado: (2017)

Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren’s disease in 788 patients: the Austrian register
por: Rohit, Arora, et al.
Publicado: (2019)

TAK1ng control: TAK1 restrains NLRP3 activation
por: Mangan, Matthew Stephen, et al.
Publicado: (2018)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

The relation of age at menarche with age at natural menopause: a population study of 336 788 women in Norway
por: Bjelland, E K, et al.
Publicado: (2018)

788 Are Clinical Prediction Scores in Community-Acquired Pneumonia Equally Reliable Across Various Etiologic Categories?
por: Abers, Michael S., et al.
Publicado: (2014)

788. Enterobacter cloacae Infection Characteristics and Outcomes in Military Personnel who Sustained Trauma in Iraq and Afghanistan
por: Bennett, William N, et al.
Publicado: (2021)

788 Upper Extremity and Lower Extremity Net Devices for Use after Application of Cultured Epidermal Autograft
por: Hayes, Callie J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o2cuve7fuju0ueou9osd1ierqf